Document is current
Any future updates will be listed below
-
Authors
Jesudian, Arun
Gagnon-Sanschagrin, Patrick
Maitland, Jessica https://orcid.org/0009-0002-6804-319X
Yokoji, Kana
Guérin, Annie
Heimanson, Zeev
Samson, Aaron
Olujohungbe, Olamide
Bumpass, Brock
-
Funding
Funding for this research was provided by:
Bausch Health US, LLC
- License Information
-
More Information
Article History
Received: 14 October 2024
Accepted: 12 February 2025
First Online: 7 April 2025
Declarations
:
: Arun Jesudian served as a consultant to Bausch Health US, LLC and received speaking fees from Salix Pharmaceuticals at the time this work was performed. Patrick Gagnon-Sanschagrin, Jessica Maitland, Kana Yokoji, and Annie Guérin are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Bausch Health US, LLC, which funded the development and conduct of this study and manuscript. Zeev Heimanson is an employee of Salix Pharmaceuticals. Aaron Samson is a Rutgers Institute for Pharmaceutical Industry Fellow at Bausch Health US, LLC. Olamide Olujohungbe is an employee of Bausch Health US, LLC. Brock Bumpass was an employee of Bausch Health US, LLC at the time the study was conducted and is currently an employee of Alnylam.
: Data are de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act (HIPAA); therefore, no review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4).
